G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests

Malaria Journal

Meeting Report

Qin Cheng¹  Janice Culpepper²  Pongwit Bualombai³  Jimee Hwang⁴  Issarang Nuchprayoon⁵  Nwe Nwe Oo⁶  Ari Winasti Satyagraha⁷  Kevin Baird⁸  Justin Green⁹  Nick Carter⁹  Didier Menard^1,10  Chi Eziefula^1,11  Judith Recht^1,12  Arantxa Roca^1,13  Lorenz Von Seidlein^1,14  Anup Anvikar^1,15  Siv Sovannaroth^1,16  Gonzalo J Domingo^1,17  Sarah McGray^1,17  Kun Qian^1,17  Pooja Bansil^1,17  Wadchara Pumpradit^1,18  Mark Fukuda^1,19  Germana Bancone^2,20  Francois Nosten^2,21  Wichai Satimai^2,22  Marcus Lacerda^2,23  Lasse S Vestergaard^2,24 

[1] Australian Army Malaria Institute, Enoggera, Australia;Bill & Melinda Gates Foundation, Seattle, USA;Bureau of Vector Borne Diseases, Bangkok, Thailand;Centers for Disease Control and Prevention; Global Health Group, University of California, San Francisco, USA;Chulalongkorn University, Bangkok, Thailand;Department of Medical Research, Lower Myanmar, Yangon, Myanmar;Eijkman Institute for Molecular Biology, Jakarta, Indonesia;Eijkman- Oxford Clinical Research Unit, Jakarta, Indonesia;GlaxoSmithKline, Stockley Park, Uxbridge, UK;Institut Pasteur du Cambodge, Phnom Penh, Cambodia;London School of Hygiene and Tropical Medicine, London, UK;Mahidol Oxford Research Unit, Bangkok, Thailand;Malaria Consortium, Phnom Penh, Cambodia;Menzies School of Health Research, Darwin, Australia;National Institute of Malaria Research, New Delhi, India;National Malaria Control Programme, Phnom Penh, Cambodia;PATH, 2201 Westlake Avenue, Suite 200, 98121, Seattle, WA, USA;PATH, Bangkok, Thailand;President's Malaria Initiative, Greater Mekong Subregion, Bangkok, Thailand;Shoklo Malaria Research Unit, Mae Sot, Thailand;Shoklo Malaria Research Unit, Mae Sot, Thailand;Mahidol Oxford Research Unit, Bangkok, Thailand;Thailand Ministry of Public Health, Bangkok, Thailand;University of the State of Amazonas, Manaus, Brazil;WHO/WPRO, Manila, Philippines;

关键词: Malaria;    G6PD Deficiency;    Radical Cure;    Vivax Infection;    National Malaria Control Programme;   

DOI  :  10.1186/1475-2875-12-391

 received in 2013-09-11, accepted in 2013-10-30,  发布年份 2013

来源: Springer

【 摘 要 】

Malaria elimination will be possible only with serious attempts to address asymptomatic infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax. Currently available drugs that can completely clear a human of P. vivax (known as “radical cure”), and that can reduce transmission of malaria parasites, are those in the 8-aminoquinoline drug family, such as primaquine. Unfortunately, people with glucose-6-phosphate dehydrogenase (G6PD) deficiency risk having severe adverse reactions if exposed to these drugs at certain doses. G6PD deficiency is the most common human enzyme defect, affecting approximately 400 million people worldwide.Scaling up radical cure regimens will require testing for G6PD deficiency, at two levels: 1) the individual level to ensure safe case management, and 2) the population level to understand the risk in the local population to guide Plasmodium vivax treatment policy. Several technical and operational knowledge gaps must be addressed to expand access to G6PD deficiency testing and to ensure that a patient’s G6PD status is known before deciding to administer an 8-aminoquinoline-based drug.In this report from a stakeholder meeting held in Thailand on October 4 and 5, 2012, G6PD testing in support of radical cure is discussed in detail. The focus is on challenges to the development and evaluation of G6PD diagnostic tests, and on challenges related to the operational aspects of implementing G6PD testing in support of radical cure. The report also describes recommendations for evaluation of diagnostic tests for G6PD deficiency in support of radical cure.

【 授权许可】

CC BY   
© Domingo et al.; licensee BioMed Central Ltd. 2013